TY - JOUR
T1 - Peginterferon alfa-2a and ribavirin in latino and non-latino whites with hepatitis C
AU - Rodriguez-Torres, Maribel
AU - Jeffers, Lennox J.
AU - Sheikh, Muhammad Y.
AU - Rossaro, Lorenzo
AU - Ankoma-Sey, Victor
AU - Hamzeh, Fayez M.
AU - Martin, Paul
PY - 2009/1/15
Y1 - 2009/1/15
N2 - BACKGROUND: Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. The primary end point was a sustained virologic response. We enrolled Latinos whose parents and grandparents spoke Spanish as their primary language; nonwhite Latinos were excluded. RESULTS: Baseline characteristics were similar in the Latino and non-Latino groups, although higher proportions of Latino patients were 40 years of age or younger, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of more than 27 or more than 30, and had cirrhosis. The rate of sustained virologic response was higher among non-Latino whites than among Latinos (49% vs. 34%, P
AB - BACKGROUND: Race has been shown to be a factor in the response to therapy for hepatitis C virus (HCV) infection, and limited data suggest that ethnic group may be as well; however, Latinos and other ethnic subpopulations have been underrepresented in clinical trials. We evaluated the effect of Latino ethnic background on the response to treatment with peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who had not been treated previously. METHODS: In a multicenter, open-label, nonrandomized, prospective study, 269 Latino and 300 non-Latino whites with HCV infection received peginterferon alfa-2a, at a dose of 180 μg per week, and ribavirin, at a dose of 1000 or 1200 mg per day, for 48 weeks, and were followed through 72 weeks. The primary end point was a sustained virologic response. We enrolled Latinos whose parents and grandparents spoke Spanish as their primary language; nonwhite Latinos were excluded. RESULTS: Baseline characteristics were similar in the Latino and non-Latino groups, although higher proportions of Latino patients were 40 years of age or younger, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of more than 27 or more than 30, and had cirrhosis. The rate of sustained virologic response was higher among non-Latino whites than among Latinos (49% vs. 34%, P
UR - http://www.scopus.com/inward/record.url?scp=58349122475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58349122475&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa0805062
DO - 10.1056/NEJMoa0805062
M3 - Article
C2 - 19144941
AN - SCOPUS:58349122475
SN - 0028-4793
VL - 360
SP - 257
EP - 267
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 3
ER -